# A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia

> **NCT05919823** · PHASE3 · COMPLETED · sponsor: **Karuna Therapeutics, Inc., a Bristol Myers Squibb company** · enrollment: 202 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Xanomeline and Trospium Chloride Capsules
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05919823
- **Lead sponsor:** Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-29
- **Primary completion:** 2024-09-16
- **Final completion:** 2024-12-09
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05919823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05919823, "A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05919823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*